IPH5201

Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018

March 15, 2018

First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...

Publications & Presentations

We are proud to contribute to the scientific advancements on innate immunity and NK cells. Since our founding in 1999, our researchers have been published in several high impact factor journals, highlighting our expertise in NK cell modulation and commitment to the highest quality science.

Read more about Publications & Presentations

First-in-class CD39 checkpoint inhibitor presented at the AACR meeting

April 19, 2016

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the...

AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology

March 17, 2016

Five posters presented by Innate Pharma and collaborators; New data further supporting the rationale of four of Innate’s clinical and preclinical programs; New checkpoint inhibitor program targeting...

Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program

January 10, 2016

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a...

What is IPH5201?

IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
CD39 is an extracellular membrane-bound enzyme that is expressed on both tumor infiltrating immune cells and stromal cells, in several cancer types.

Read more about IPH5201

Subscribe to IPH5201

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers